OMass’s molecule is vying to become an alternative to a Neurocrine Biosciences drug that is currently the only FDA-approved therapy for congenital adrenal hyperplasia. But Vertex Pharmaceuticals could also compete with a drug candidate from a recent acquisition.
The post Startup OMass Secures $310M to Advance Drug for Rare Endocrine Disorder appeared first on MedCity News.
